News

American Council on Science and Health2d
Possible New Era in Pain Management: FDA Approves Novel Non-Opioid Analgesic
The availability of suzetrigine may represent a critical step in addressing the nation’s pain management crisis. While ...
Vertex's Journavx Launch Sparks Optimism, Analyst Sees 'Two Potential Upside Levers'
Vertex Pharmaceuticals sees early success with Journavx painkiller, potential revenue growth from drug and gene therapy.
Don't Try to Time the Market: These 2 Stocks Are Buys Regardless of What Happens Next
Equity markets have been seesawing for the past two weeks. Stocks fell hard after President Donald Trump announced his tariff ...
University of Massachusetts Lowell3d
Biochemistry Seminar: Speaker Hada Fongha Leong 4/17
UMass Lowell Recognized as Top Research Institution with R1 Classification Read More ⁠ ...
Neuroscience News5d
Why You Sometimes Don’t Feel Pain Until It’s Too Late
New research highlights how the brain’s own chemistry can suppress pain, explaining why severely injured individuals, like ...
Physician's Weekly23d
Addressing Acute Pain & Related Challenges: Will Recent FDA Approval of a Novel Non-Opioid Analgesic Be a Game Changer?
FDA approval of a novel non-opioid analgesic will hopefully address the needs of many patients with acute pain and improve clinical outcomes and QOL.
Nature8d
New approaches to opioid-free pain treatment
On 30 January 2025, the US Food and Drug Administration (FDA) approved the non-opioid medication suzetrigine (JOURNAVX), which ... is an important step in pain management.